FDA approves GSK's Nucala for asthma

FDA approved Nucala mepolizumab ( SB-240563) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) as an add-on maintenance treatment for severe asthma with eosinophilic inflammation in patients aged 12 and older.

GSK plans to launch Nucala by YE15 at a wholesale acquisition cost (WAC) of $2,500 per single-use vial. The drug is administered in a 100 mg dose subcutaneously every four weeks. ...